Clinical trials: Movement, Involuntary, open to volunteers
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Movement Disorders
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications.
- Trial name
- NCT00001208
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)